Randomized trial in postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer in the presurgical setting to test whether the addition of GDC-0032 to letrozole gives added benefit Randomizovaná studie u postmenopauzálních žen s ER pozitivním/ HER2 negativním nádorem prsu ověřující přínos kombinované předoperační léčby GDC-0032 a Letrozolu The primary objective of this study is to evaluate the efficacy of letrozole plus GDC-0032 versus letrozole plus placebo in women with ER+/HER2- early stage breast cancer, as measured by the following...

• Country None
• organs None
• Specialty None

Study of the novel cancer drug GDC-0941 (or placebo) in combination with : a) the approved anticancer drugs carboplatin and paclitaxel; and b) the approved anticancer drugs carboplatin, paclitaxel and bevacizumab in previously untreated patients with advanced non-small cell lung cancer Part I •To evaluate the efficacy (as measured by PFS) of GDC-0941 340mg+carboplatin+paclitaxel (Arm A) versus carboplatin+paclitaxel (Arm B) in all patients with squamous NSCLC •To evaluate the effi...

• Country None
• organs None
• Specialty None

A Study of the Safety and Efficacy of GDC 0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus To evaluate the clinical efficacy of GDC-0853 in combination with standard of care (SOC)

• Country None
• organs None
• Specialty None

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE LEBRIKIZUMAB (MILR1444A) IN ADULT PATIENTS WITH ASTHMA WHO ARE NOT TAKING INHALED CORTICOSTEROIDS (MOLLY) The main objectives of this study are as follows; - To evaluate the efficacy of different doses of lebrikizumab compared with placebo as measured by relative change in pre-bronchodilator FEV1. -...

• Country None
• organs None
• Specialty None

A clinical study comparing the effects of chemotherapy plus Avastin to chemotherapy plus Avastin plus a new drug (MEGF0444A) in patients with non-small cell lung cancer who have not received chemotherapy before To evaluate the efficacy of MEGF0444A used in combination with carboplatin + paclitaxel + bevacizumab therapy in patients with advanced or recurrent non-squamous NSCLC, as measured by progression-free...

• Country None
• organs None
• Specialty None

FRANC : Essai de phase 2, randomisé évaluant l’efficacité et la tolérance de l’association d’ABT-263 et du rituximab intensif, chez des patients ayant une leucémie lymphoïde chronique à lymphocyte B. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité de l’association d’ABT-263 et de rituximab intensif chez des patients ayant une leucémie lymphoïde chronique à lymphocyte B. Les patients seront rép...

• Country France
• organs Leucémies chroniques
• Specialty Thérapies Ciblées

GENENTECH SHH4476g : Essai de phase 2 évaluant l'efficacité et la tolérance d'un inhibiteur de la voie hedgehog (GDC-0449) chez des patients ayant un carcinome baso-cellulaire avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A phase II, multicenter, single-arm, two-cohort trial evaluating the efficacy and safety of GDC-0449 in patients with advanced basal cell carcinoma

• Country France
• organs Peau - autres
• Specialty Thérapies Ciblées

A Study of ARN-810 (GDC-0810) Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Phase Ia: To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) and assess the safety of single agent GDC-0810 in postmenopausal women with locally advanced or metastat...

• Country None
• organs None
• Specialty None

GENENTECH PIM4605g : Essai de phase 1 évaluant la tolérance du GDC-0980, chez des patients ayant une tumeur solide ou un lymphome non hodgkinien réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] An open-label, phase I, dose-escalation study evaluating the safety and tolerability of GDC-0980 administered once weekly in patients with refractory solid tumors or non-hodgkin's lymphoma.

• Country France
• organs Tumeurs solides, Lymphomes non hodgkinien
• Specialty Thérapies Ciblées

Étude GO29779 : étude de phase 1, en escalade de dose, évaluant la tolérance d’une combinaison de deux immunothérapies, GDC0919, un inhibiteur de IDO et l’atezolizumab, un anticorps anti-PD-L1, chez des patients ayant une tumeur solide localement avancée ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] GO29779 : Étude de phase IB, en ouvert, avec escalade de doses visant à évaluer la sécurité et la pharmacologie du GDC-0919 administré avec l'atezolizumab chez des patients atteints de tumeurs solides...

• Country France
• organs Tumeurs solides
• Specialty Immunothérapie - Vaccinothérapie